A recently published retrospective study (2024) of 122 patients with RA treated with tofacitinib found a significant improvement (p<0.0001) in the DAS28-CRP, Clinical Disease Activity Index, and Simplified Disease Activity Index at three, six, and 12 months of follow-up, with a persistence rate of 89.35%. The gene discussed is CRP; the disease is rheumatoid arthritis.